WO1996030386A1
(fr)
*
|
1995-03-31 |
1996-10-03 |
Drug Delivery System Institute, Ltd. |
Derives d'amidite et derives d'oligonucleotides
|
US5855911A
(en)
*
|
1995-08-29 |
1999-01-05 |
Board Of Regents, The University Of Texas System |
Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
|
DE19631189A1
(de)
*
|
1996-08-02 |
1998-02-05 |
Max Delbrueck Centrum |
Neuartige kationische Amphiphile für den liposomalen Gentransfer
|
US6977244B2
(en)
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US7704962B1
(en)
|
1997-10-03 |
2010-04-27 |
Board Of Regents, The University Of Texas System |
Small oligonucleotides with anti-tumor activity
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
GB2372502B
(en)
*
|
2000-12-12 |
2004-10-13 |
Imperial College |
Carbohydrate compounds containing cholesterol and their use
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
DK2539451T3
(da)
|
2010-02-24 |
2016-04-04 |
Arrowhead Res Corp |
Sammensætninger til målrettet tilførsel af siRNA
|
EP3766975A1
(en)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
US8501930B2
(en)
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
JP2014504295A
(ja)
|
2010-12-17 |
2014-02-20 |
アローヘッド リサーチ コーポレイション |
siRNA用ガラクトースクラスター−薬物動態調節剤標的指向部分
|
US8932572B2
(en)
|
2011-08-26 |
2015-01-13 |
Arrowhead Madison Inc. |
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
|
US20140100178A1
(en)
*
|
2012-10-04 |
2014-04-10 |
Aslam Ansari |
Composition and methods for site-specific drug delivery to treat malaria and other liver diseases
|
EP2920304B1
(en)
|
2012-11-15 |
2019-03-06 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugates
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
EP2951305B1
(en)
|
2013-01-30 |
2018-08-15 |
F.Hoffmann-La Roche Ag |
Lna oligonucleotide carbohydrate conjugates
|
SG10201908122XA
(en)
|
2013-06-27 |
2019-10-30 |
Roche Innovation Ct Copenhagen As |
Antisense oligomers and conjugates targeting pcsk9
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
|
MX2017011422A
(es)
|
2015-03-17 |
2017-11-10 |
Arrowhead Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen del factor xii.
|
CA2991639A1
(en)
|
2015-08-07 |
2017-02-16 |
Arrowhead Pharmaceuticals, Inc. |
Rnai therapy for hepatitis b virus infection
|
JOP20210043A1
(ar)
|
2015-10-01 |
2017-06-16 |
Arrowhead Pharmaceuticals Inc |
تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
|
EP3426261A4
(en)
|
2016-03-07 |
2020-03-25 |
Arrowhead Pharmaceuticals, Inc. |
TARGETED LIGANDS FOR THERAPEUTIC CONNECTIONS
|
RS61528B1
(sr)
|
2016-03-14 |
2021-04-29 |
Hoffmann La Roche |
Oligonukleotidi za smanjenje ekspresije pd-l1
|
EP3228326A1
(en)
|
2016-04-05 |
2017-10-11 |
Silence Therapeutics GmbH |
Nucleic acid linked to a trivalent glycoconjugate
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
AU2017320582B2
(en)
|
2016-09-02 |
2023-11-16 |
Arrowhead Pharmaceuticals, Inc |
Targeting ligands
|
IL267959B2
(en)
|
2017-01-10 |
2024-07-01 |
Arrowhead Pharmaceuticals Inc |
Alpha-1 antitrypsin (AAT) RNAi agents, preparations containing AAT RNAi agents and their uses
|
EP3385272A1
(en)
|
2017-04-05 |
2018-10-10 |
Silence Therapeutics GmbH |
Further novel oligonucleotide-ligand conjugates
|
WO2018185253A1
(en)
|
2017-04-05 |
2018-10-11 |
Silence Therapeutics Gmbh |
Ligand modified double-stranded nucleic acids
|
WO2018185252A1
(en)
|
2017-04-05 |
2018-10-11 |
Silence Therapeutics Gmbh |
Nucleic acid conjugates
|
EP3385381A1
(en)
|
2017-04-05 |
2018-10-10 |
Silence Therapeutics GmbH |
Products and compositions
|
EP3385380A1
(en)
|
2017-04-05 |
2018-10-10 |
Silence Therapeutics GmbH |
Products and compositions
|
EP3483269A1
(en)
|
2017-11-13 |
2019-05-15 |
Silence Therapeutics GmbH |
Products and compositions
|
US11414660B2
(en)
|
2017-04-05 |
2022-08-16 |
Silence Therapeutics Gmbh |
Products and compositions
|
EP3550022A1
(en)
|
2018-04-05 |
2019-10-09 |
Silence Therapeutics GmbH |
Products and compositions
|
DK3607069T3
(da)
|
2017-04-05 |
2022-11-21 |
Silence Therapeutics Gmbh |
Produkter og sammensætninger
|
EP4219714A3
(en)
|
2017-04-05 |
2023-08-30 |
Silence Therapeutics GmbH |
Rna interference mediated inhibition of tmprss6
|
CR20200108A
(es)
|
2017-09-11 |
2020-06-28 |
Arrowhead Pharmaceuticals Inc |
Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
|
TN2020000038A1
(en)
|
2017-09-14 |
2021-10-04 |
Arrowhead Pharmaceuticals Inc |
Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
|
UA126931C2
(uk)
|
2017-10-16 |
2023-02-22 |
Ф. Хоффманн-Ля Рош Аг |
МОЛЕКУЛИ НУКЛЕЇНОВИХ КИСЛОТ ДЛЯ ЗМЕНШЕННЯ РІВНЯ мРНК PAPD5 І PAPD7 ДЛЯ ЛІКУВАННЯ ІНФЕКЦІЙНОГО ГЕПАТИТУ B
|
JP7473472B2
(ja)
|
2017-10-17 |
2024-04-23 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
アシアロ糖タンパク質受容体1の発現を阻害するためのRNAi剤および組成物
|
WO2019092282A1
(en)
|
2017-11-13 |
2019-05-16 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of aldh2 in a cell
|
US11873489B2
(en)
|
2017-11-13 |
2024-01-16 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
|
EP3483270A1
(en)
|
2017-11-13 |
2019-05-15 |
Silence Therapeutics GmbH |
Products and compositions
|
MX2020004897A
(es)
|
2017-11-13 |
2020-10-05 |
Silence Therapeutics Gmbh |
Acidos nucleicos para inhibir la expresion de lpa en una celula.
|
EP3550021A1
(en)
|
2018-04-05 |
2019-10-09 |
Silence Therapeutics GmbH |
Products and compositions for inhibiting expression of a target gene
|
KR20200140322A
(ko)
|
2018-04-05 |
2020-12-15 |
사일런스 테라퓨틱스 게엠베하 |
안티센스 가닥의 5' 단부에 비닐포스포네이트를 갖는 siRNA
|
MX2020013366A
(es)
|
2018-07-03 |
2021-03-09 |
Hoffmann La Roche |
Oligonucleotidos para modular la expresion de tau.
|
EP3598995A1
(en)
|
2018-07-26 |
2020-01-29 |
Silence Therapeutics GmbH |
Products and compositions
|
EP3844274A1
(en)
|
2018-08-28 |
2021-07-07 |
Roche Innovation Center Copenhagen A/S |
Neoantigen engineering using splice modulating compounds
|
JP7245328B2
(ja)
|
2018-11-13 |
2023-03-23 |
サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
細胞におけるlpaの発現を抑制するための核酸
|
US20220017899A1
(en)
|
2018-11-23 |
2022-01-20 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of c3 in a cell
|
EP3730617A1
(en)
|
2019-04-26 |
2020-10-28 |
Silence Therapeutics GmbH |
Nucleic acids for inhibiting expression of c3 in a cell
|
TW202045723A
(zh)
|
2019-02-07 |
2020-12-16 |
美商艾羅海德製藥公司 |
用於B型肝炎病毒感染之RNAi劑
|
WO2020173845A1
(en)
|
2019-02-26 |
2020-09-03 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide formulation method
|
US20220243202A1
(en)
|
2019-05-07 |
2022-08-04 |
Universität Bern |
Nucleic acids for inhibiting expression of pros1 in a cell
|
CN114222820A
(zh)
|
2019-06-06 |
2022-03-22 |
箭头药业股份有限公司 |
用于治疗α-1抗胰蛋白酶缺乏症(AATD)的方法
|
US20220305117A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
|
EP4022060A1
(en)
|
2019-08-27 |
2022-07-06 |
Silence Therapeutics GmbH |
Nucleic acids for inhibiting expression of c3 in a cell
|
TW202137987A
(zh)
|
2019-12-24 |
2021-10-16 |
瑞士商赫孚孟拉羅股份公司 |
用於治療hbv之靶向hbv的治療性寡核苷酸及tlr7促效劑之醫藥組合
|
JP2023509872A
(ja)
|
2019-12-24 |
2023-03-10 |
エフ. ホフマン-ラ ロシュ アーゲー |
Hbvを標的とする抗ウイルス剤及び/又はhbvの処置のための免疫調節剤の医薬組合せ
|
BR112022019241A2
(pt)
|
2020-03-26 |
2022-11-16 |
Arrowhead Pharmaceuticals Inc |
Agentes de rnai para inibição da expressão de pnpla3, composições farmacêuticas dos mesmos e métodos de uso
|
CA3184050A1
(en)
|
2020-05-27 |
2021-12-02 |
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC bioGUNE |
Nucleic acids for inhibiting expression of cnnm4 in a cell
|
WO2022060721A2
(en)
|
2020-09-15 |
2022-03-24 |
Arrowhead Pharmaceuticals, Inc. |
Methods for the reduction of z-aat protein levels
|
WO2022096424A1
(en)
|
2020-11-04 |
2022-05-12 |
Universität Bern |
Nucleic acids for inhibiting expression of pros1 in a cell
|
WO2022184852A1
(en)
|
2021-03-03 |
2022-09-09 |
Silence Therapeutics Gmbh |
Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell
|
WO2022223557A1
(en)
|
2021-04-20 |
2022-10-27 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of xdh in a cell
|
JP2024515800A
(ja)
|
2021-04-27 |
2024-04-10 |
サイレンス・セラピューティクス・ゲーエムベーハー |
骨髄増殖性障害の処置のためのTMPRSS6を標的とするsiRNA
|
US11629349B2
(en)
|
2021-06-21 |
2023-04-18 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
|
CN118234861A
(zh)
|
2021-09-02 |
2024-06-21 |
赛伦斯治疗有限责任公司 |
用于抑制细胞中的补体因子b(cfb)表达的核酸
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
WO2024126687A1
(en)
|
2022-12-16 |
2024-06-20 |
Silence Therapeutics Gmbh |
Nucleic acids conjugated to an albumin binding moiety
|